Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Aug 01, 2010 (Vol. 30, No. 14)

Genetic Alliance

URL:www.geneticalliance.org
  • Wonderful collection of links, well-organized site
  • Many disease-specific pages listed in the search contain little information

I can always appreciate a website with a clever logo—such as the Genetic Alliance’s DNA strand in which people substitute for the base pairs. And when the rest of the site delivers, well, that just makes my day.  Genetic Alliance is a nonprofit health advocacy group that provides resources about health in general, but with a specific emphasis on genetic disorders. The disease info search provides links to disease-specific resources, categorized into five groups: organizations, arts and literature, clinical description, research, and general information. Unfortunately, though, some of the entries are bare. In addition to the large number of links provided through the infosearch and organization search options, Genetic Alliance also has an entirely separate “resource repository” containing a wealth of information for the global health community.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »